Company intelligence / Profile preview

Liberation Bioindustries

Richmond, Indiana, United Statesliberation.bio ↗

Ownership: Private
Development stage: Other

Overview

The company is developing the first purpose-built, commercial-scale precision fermentation facility in the US, with a 600,000 liter capacity and dedicated downstream processing for ingredients such as recombinant dairy protein (beta-lactoglobulin); first production to begin in 2026 for customers including Vivici[1][3][6][7][8].

Modalities: ProteinRecombinant proteinBiologicEnzyme
Industry: Contract Manufacturing Organization

Partnerships

Vivici (manufacturing partnership; commercial production of Vivitein BLG)[3][8]Topian/NEOM (strategic partnership to develop fermentation facility in Saudi Arabia)[1][6][7]

Beyond the preview

Go deeper on Liberation Bioindustries.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Liberation Bioindustries.

Explore the full profile